Explore our drug delivery technology platforms
We are a world leader in pharmaceutical excipients, vaccine adjuvants and lipid delivery systems for human and veterinary applications.
Small Molecule Delivery
We offer high purity, multi-compendial, pharmaceutical excipients for small molecule drug delivery. Our portfolio of high purity excipient products and speciality chemistries solve formulation challenges and enhance drug delivery across a variety of administration routes and dosage forms.
Protein Delivery
We collaborate with you to provide tailored excipient solutions, drawing on our expertise and product portfolio to speed up formulation development and time to market. Enabling drug delivery through a wide range of highly purified excipients to improve protein formulation stability.
Nucleic Acid Delivery
We develop and manufacture innovative lipids of unparalleled purity to solve the stability and delivery issues associated with mRNA for use in vaccines and next-generation therapeutics.
Adjuvant Systems
Your partner for modern vaccine development. Our unique GMP portfolio and outstanding expertise can meet your adjuvant needs. Collaborate with our scientists to create the vaccines of tomorrow.
How we empower biologics delivery
Explore recent blogs:
Croda welcomes Thomas Riermeier as new President of Life Sciences
Croda International Plc, the company that uses smart science to create ingredients and technologies that improve lives, today announces that Dr. Thomas Riermeier has been appointed as the new...
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=4F9521E2A9CDAB872D1AA12B9BA9F4EB)
From Lab to Patient: Optimising Oncology Formulations with Purified Excipients
In 2024, we hosted a live webinar exploring the impact of our Super RefinedTM excipients on various chemotherapeutic formulations. This blog will explore some of the key learnings from the webinar.
.png?w=768&la=en-GB&focalpointcrop=1&xratio=0&yratio=0&hash=F330DFD631D5F6E81578038D37E005ED){kind=logo}
Croda’s Avanti Research expands ionizable lipid offering for LNP drug development through Certest collaboration
Avanti Polar Lipids, LLC, a wholly owned subsidiary of Croda International Plc, and Certest Biotec S.L. (Certest) are pleased to announce a strategic collaboration to expand the market’s access to...